Bio-Techne FY Conference Summary Company Overview - **Company**: Bio-Techne (NasdaqGS: TECH) - **Industry**: Life Sciences Tools - **Established**: 50 years ago - **Core Products**: 7,000 proteins and 400,000 antibodies, serving as foundational components for life science research tools [2][4] Key Business Areas 1. **Cell Therapy**: Focus on growing immune and regenerative cells to treat diseases [2][3] 2. **Proteomics**: Emphasis on proteomic analysis, with a belief in market growth potential [3][4] 3. **Spatial Biology**: Investigating tissue interactions to assess therapy effectiveness [3][4] 4. **Molecular Diagnostics**: Capable of analyzing difficult-to-read genes, addressing gaps in next-generation sequencing (NGS) [3][4] Recent Financial Performance - **Q1 2026 Results**: - Cell therapy business showed rapid growth, with 60% and 90% growth in previous quarters [5] - Two major customers received FDA Fast Track approval, leading to expected revenue boosts [5][22] - Large pharma customers continued double-digit growth for three consecutive quarters [6] - China market showed positive growth for two consecutive quarters [6] - Margins improved to 29.9%, exceeding the forecast of 20% [6] Market Insights - **Biopharma Market**: - Accounts for 50% of revenue; large pharma contributes 30% of that [8] - Large pharma showed resilience despite tariff concerns, while biotech funding declined mid-teens year-over-year [8][9] - Recent M&A activity and lower interest rates are expected to stabilize biotech funding [9] - **Academic Research Market**: - Represents 20% of revenue; U.S. academic research is 12% and Europe is 8% [10] - U.S. market faced turbulence due to budget cuts and funding shifts, but bipartisan support is anticipated [11] - Shift in funding focus from infectious diseases to neurology, oncology, and weight management [11][12] - **China Market**: - Historically significant growth driver, currently at 8% of revenue [14] - Increased sensitivity towards life sciences post-COVID, with a focus on novel modalities [15] - Expected growth in the mid-teens as activity levels improve [16] Product Innovations - **R&D Investment**: Over 8% of revenues reinvested into R&D [17] - **Key Innovations**: - AI-enhanced protein design for improved stability and sensitivity [17] - ProPak for cell therapy, reducing contamination risks [18] - Leo protein analysis instrument for high-volume testing [18] - Multi-omics method for spatial biology [19] - ESR1 breast cancer test for treatment resistance [20] Strategic Acquisitions - **Wilson Wolf**: Bio-Techne plans to acquire the remaining 80% of Wilson Wolf by 2027, enhancing its cell therapy capabilities [24][25] Market Outlook - **Fiscal 2026 Expectations**: - Anticipated single-digit growth, with potential for double-digit growth in normalized market conditions [28][29] - Recovery expected in biotech and academic markets, with stabilization in large pharma [30][31] - Continued market share gains anticipated in protein analytics and spatial biology [32] Conclusion - Bio-Techne is positioned for growth through strategic innovations, market recovery, and a focus on high-demand areas within the life sciences sector. The company is optimistic about future performance as market conditions stabilize and improve.

天眼查App显示，近日，广州市泰维生物科技有限公司成立，注册资本0.1万人民币，经营范围为技术进 出口;货物进出口;食品添加剂销售;消毒剂销售（不含危险化学品）;农用薄膜销售;非食用鱼油及制品销 售;化肥销售;肥料销售;水产品零售;水产品批发;生物农药技术研发;水污染治理;水环境污染防治服务;日 用化学产品销售;生物有机肥料研发;复合微生物肥料研发;化妆品零售;化妆品批发;土壤与肥料的复混加 工;农林牧渔专用仪器仪表销售;互联网销售（除销售需要许可的商品）;海水养殖和海洋生物资源利用装 备销售;互联网安全服务;食用农产品批发;技术服务、技术开发、技术咨询、技术交流、技术转让、技术 推广;生物饲料研发;化工产品销售（不含许可类化工产品）;卫生用品和一次性使用医疗用品销售;中草 药收购;农业科学研究和试验发展;畜牧渔业饲料销售;饲料原料销售;饲料添加剂销售;农药零售;农药批发; 兽药经营;药品零售;药品进出口;药品批发;水产养殖;农作物种子经营;农作物种子进出口。 ...

Group 1 - The pharmaceutical sector continues to adjust, with various indices such as the Hang Seng Innovative Drug Index and the CSI Hong Kong Pharmaceutical and Health Comprehensive Index declining by 1.2% [1] - Despite the downturn, there is a significant capital inflow, with the Hang Seng Innovative Drug ETF (159316) seeing a net subscription of over 80 million units throughout the day [1] - The fundamental reason for the pharmaceutical industry's ability to reach new highs despite ongoing challenges is the persistent demand for pharmaceuticals and the increasing number of unmet needs, alongside continuous R&D investments by pharmaceutical companies [1] Group 2 - China has become a significant player in global innovative drug research and development, with overseas licensing activity continuing to rise year after year [1] - The pharmaceutical industry is entering a revenue era driven by innovation [1]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 3D 生物打印 是一种三维生物制造技术，用于精确地排列细胞和含细胞生物材料 （生物墨水） ，以构建具有所需功能的立体生物组织。通常，生物墨水依靠水凝 胶基质在生物打印之前、期间或之后稳定并交联构建体。尽管此类方法推进了仿生学的发展，但其难以实现体内细胞的高密度，且大量水凝胶成分可能会阻碍细 胞间相互作用，导致表型丧失并降低组织功能。 近年来，无支架的 3D 生物打印技术被提出以解决细胞密度问题，但这类方法通常依赖于挤出式生物打印，难以无法达到复杂组织所需的分辨率和复杂度。 2025 年 12 月 8 日， 哈佛医学院 张宇 教授团队在国际大奖学术期刊 Cell 上发表了题为： Biomaterial-minimalistic photoactivated bioprinting of cell- dense tissues 的研究论文。 王冕 （现为同济大学研究员） 、 李婉露 （现为 上海交通大学 助理教授） 、 郝晋 （现为上海交通大学助理研究员） 、 蔡玲 为 论文共同第一作者 。 该研究开发了一种去材料化、无支架的 高细胞密度生物墨水 （ Cell-dense ...

Group 1 - Hunan Juntong Biotechnology Co., Ltd. has been established with a registered capital of 18.8 million RMB [1] - The legal representative of the company is Shen Weiyi [1] - The company's business scope includes food sales, internet food sales, and alcoholic beverage operations, subject to necessary approvals [1] Group 2 - The company is authorized to engage in various general projects such as the sale of pre-packaged food, sales of commercial and dining service equipment, and sales of plastic products [1] - It also includes wholesale and retail of edible agricultural products, domestic trade agency, and trade brokerage [1] - The company can provide management consulting, information consulting services, and technical services, development, and promotion [1]

Core Viewpoint - The Hong Kong Stock Exchange has launched the Hang Seng Tech 100 Index, which aims to track the performance of the largest 100 technology companies listed in Hong Kong, incorporating strict liquidity and R&D growth criteria for inclusion [1][2]. Group 1: Index Composition and Criteria - The index requires constituent stocks to have an average daily trading volume of at least HKD 20 million over the past six months and either R&D expenditure accounting for over 3% of revenue or revenue growth exceeding 5% over the past two years [1][2]. - Notable companies included in the index are Tencent Holdings, Alibaba-W, CATL, Xiaomi Group-W, BYD Company, Meituan-W, SMIC, and WuXi AppTec [1][2]. - The index covers six major innovation themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [2]. Group 2: Methodology and Adjustments - The index uses a free-float market capitalization weighting method, with a maximum weight of 12% for any single constituent [2]. - Constituents are reviewed and adjusted biannually, with data cut-off dates at the last trading day of April and October [2]. - Stocks with low liquidity or poor fundamentals, such as R&D spending below 3% or revenue growth below 5%, will be excluded [2]. Group 3: Market Dynamics and Investor Appeal - The index is designed to filter out technology stocks that combine market popularity with growth certainty, addressing investor demand for diversified technology investment options [3][11]. - The index includes only stocks eligible for the Stock Connect program, catering to both international and mainland Chinese investors [5]. - The introduction of the index is expected to enhance investment opportunities in the technology sector, particularly as the number of technology companies listed in Hong Kong has surged [9][11]. Group 4: Comparison with Existing Indices - The Hang Seng Tech 100 Index differs from the Hang Seng Tech Index by including a broader range of companies across various technology sectors, while the latter focuses more on internet and fintech giants [7][8]. - The total market capitalization of the Hang Seng Tech 100 Index constituents is approximately HKD 19.43 trillion, with major players like Tencent Holdings at HKD 5.53 trillion, Alibaba-W at HKD 2.93 trillion, and CATL at HKD 2.31 trillion [7]. - In contrast, the Hang Seng Tech Index has a total market capitalization of about HKD 12.65 trillion, primarily consisting of larger industry leaders [7]. Group 5: Future Developments - The launch of the index is closely tied to the recent surge in technology IPOs in Hong Kong, with 97 companies listed this year, raising a net amount of HKD 231.9 billion, a 237% increase from the previous year [9][11]. - The Hong Kong Stock Exchange has established a "Tech Company Fast Track" to facilitate the listing of specialized technology and biotech firms, further stimulating interest in the sector [11]. - An agreement has been reached with E Fund Management to launch an ETF tracking the Hang Seng Tech 100 Index, aimed at meeting the strong demand from mainland investors for technology investment opportunities [13].

(责任编辑：田云绯) 亚辉龙于2021年5月17日在上交所科创板上市，公开发行的股份数4,100.0000万股，发行价格为 14.80元/股，保荐机构为中信证券股份有限公司，保荐代表人为孙炎林、王栋。 上市当日，亚辉龙开盘报65.00元，盘中最高报73.80元，为上市以来最高点。 亚辉龙募集资金总额为60,680.00万元，募集资金净额为54,133.44万元。亚辉龙最终募集资金净额较 原计划少19177.56万元。亚辉龙2021年5月12日发布的招股说明书显示，公司计划募集资金73,311.00万 元，分别用于研发中心升级及产能扩充项目、信息系统升级建设项目、营销体系建设与品牌推广项目、 补充流动资金。 亚辉龙上市发行费用为6,546.56万元，其中中信证券获得保荐及承销费用4,368.96万元。 中国经济网北京12月9日讯 亚辉龙(688575.SH)昨日晚间发布控股股东、实际控制人兼董事长及其一 致行动人权益变动触及1%整数倍暨董事长及部分高管兼核心技术人员减持股份结果公告。 公司于2025年8月19日披露了《深圳市亚辉龙生物科技股份有限公司控股股东、实际控制人兼董事 长及部分高管兼核心技术人员减持股份 ...

央视网消息：据"桂林龙胜"公众号消息，桂林市龙胜生态环境局12月9日通报，12月8日7时30分许，该 局接到龙脊镇人民政府报告和群众举报，称龙脊镇金江河黄洛河段水面出现白色泡沫。事情发生后，该 局迅速会同龙脊镇人民政府前往现场进行实地核查。 经调查，发现系桂林长发小寨生物科技有限公司的废水蓄水罐部分废水外溢，流入金江河黄洛河段，致 使水面出现白色泡沫。龙胜生态环境局立即责令涉事企业停业整改，并委托第三方检测公司按照操作规 范在事发地多处进行了样本采集，后续将根据调查结果依法依规作出相应处理。 ...

Core Insights - The seminar focused on the integration of synthetic biology and modern animal husbandry in Pingliang, aiming to establish a model for high-quality livestock industry in the western region of China [1] Group 1: Event Overview - The seminar was held on December 8, organized by various agricultural and scientific institutions from Tianjin and Pingliang, with over 50 participants including experts and local practitioners [1] - The event aimed to deepen technological cooperation between Tianjin and Gansu, emphasizing the collaborative model of "technology research in Tianjin, application in Pingliang" [1] Group 2: Key Presentations - Chen Jiexin, Vice President of Pingliang Agricultural Science Institute, highlighted synthetic biology as a core engine for agricultural modernization and industry upgrading, viewing the seminar as a valuable opportunity for collaboration [2] - Dr. Ma Yi, Chief Expert of Tianjin Dairy (Meat Sheep) Industry Technology System Innovation Team, discussed the importance of technological innovation in the livestock industry and proposed specific suggestions for integrating key technologies [2] - Zhang Xiaoli, Deputy General Manager of Baikui Rui (Tianjin) Biotechnology, presented on the applications of synthetic biology in agriculture, emphasizing its role in producing functional proteins and probiotics, and reducing antibiotic use [2] Group 3: Industry Perspectives - Zhang Tianti, Chairman of Auchan Yuan Intelligent Equipment Co., Ltd., discussed the potential of synthetic biology to cultivate nutrient-enhanced super crops and promote high-end health products through biomanufacturing [3] - The seminar included interactive discussions where local technicians engaged with experts on technology adaptability and the transformation of scientific achievements [3] - The event was seen as a model for technological empowerment in agriculture, promoting collaboration between eastern and western regions of China [3]

天眼查App显示，近日，黑龙江省晟沃生物科技有限公司成立，法定代表人为魏续宝，注册资本30万人 民币，经营范围为一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；复合 微生物肥料研发；生物质能技术服务；生物有机肥料研发；生物饲料研发；农林废物资源化无害化利用 技术研发；装卸搬运；土地整治服务；农业机械服务；农业机械租赁；普通货物仓储服务（不含危险化 学品等需许可审批的项目）；化肥销售；农业专业及辅助性活动；生态环境材料销售；土壤污染治理与 修复服务；土壤环境污染防治服务；肥料销售。许可项目：肥料生产；道路货物运输（不含危险货 物）。 ...